‘Global Cardiovascular Devices Market Worth $54.2bn In 2021’ Says Visiongain Report

29 August 2018
Pharma

Visiongain’s new report Global Cardiovascular Devices Market Forecast 2017-2027: Diagnostics & Monitoring, Surgical, ECG, Holter Monitors, Event Monitors, Implantable Loop Recorders, Ultrasound, Echocardiograms, Doppler Foetal Monitors, CT-Scan, PET/SPECT, Cardiac CT MRI, Stents, Valves, Pacemakers, Occlusion Devices, Cannulae, Electrosurgical Devices, Accessories/Consumables, Guidewires, Catheters indicates that the global cardiovascular devices market will see $54.2bn in spending in 2021.

The global cardiovascular devices market was valued at $40.05bn in 2016. Visiongain estimates that this market will grow at a CAGR of 6.4% in the first half of the forecast period and reach $54.22bn in 2021.This market is estimated to grow faster in the second half of the forecast period, growing at a CAGR of 7.1% and reach $81.38bn in 2027. The global cardiovascular devices market is estimated to grow at a CAGR of 6.7% from 2017 to 2027.

The lead analyst of the report said: “The global cardiovascular devices market is anticipated to show considerable growth during the forecast period. Cardiovascular diseases are the leading cause of deaths in the world. High prevalence of cardiovascular diseases (CVD), technical advancement and rising awareness regarding early diagnosis and prevention solutions are some of the prime factors impacting the growth of the global cardiovascular devices market positively.

On the other hand, requirement of skilled professionals for usage of commercially available technologies such as PET/SPECT, placing implantable loop recorder and stents is hindering the growth of the market.”

The 142 page report contains 130 charts (tables and figures) that add visual analysis in order to explain the developing trends within the Global Cardiovascular Devices Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Surgical Devices as well as Diagnostics and Monitoring Devices.
The 142 page report offers market forecasts and analysis for 13 leading national markets. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the cardiovascular devices market.

The Global Cardiovascular Devices Market Forecast 2017-2027: Diagnostics & Monitoring, Surgical, ECG, Holter Monitors, Event Monitors, Implantable Loop Recorders, Ultrasound, Echocardiograms, Doppler Foetal Monitors, CT-Scan, PET/SPECT, Cardiac CT MRI, Stents, Valves, Pacemakers, Occlusion Devices, Cannulae, Electrosurgical Devices, Accessories/Consumables, Guidewires, Catheters report will be of value to anyone who wants to better understand the cardiovascular devices market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the cardiovascular devices industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever